Company intelligence / Profile preview

PRUNUS Therapeutics

Chicago, Illinois, United Statesprunustx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

PRUNUS Therapeutics is developing the first anti-metastatic agent specifically targeting detached cancer cells, aiming to improve treatment outcomes and quality of life by sparing healthy cells. Their lead program, AcK-Lock, is in the "Pending" stage for neoplasms; no published clinical results yet.

Therapeutic areas: Oncology
Modalities: Synthetic biology-based therapeuticsSmall molecules or novel agents (inferred from anti-metastatic agent description)
Industry: Biotech

Beyond the preview

Go deeper on PRUNUS Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRUNUS Therapeutics.

Explore the full profile